Related Experiment Video

Updated: Sep 28, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Prevention of heart failure

David W Baker1

  • 1Center for Health Care Research and Policy, Case Western Reserve University at MetroHealth Medical Center, Cleveland, Ohio, USA.

Journal of Cardiac Failure
|November 2, 2002
PubMed

Insights

Preventing heart failure (HF) is crucial as cases rise. Effective treatments for hypertension and high cholesterol significantly reduce HF incidence, yet remain underutilized.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Public Health

Background:

  • Heart failure (HF) incidence is projected to increase significantly due to an aging population in the United States.
  • Urgent improvements in HF prevention strategies are necessary to mitigate this rise.

Purpose of the Study:

  • To identify and evaluate treatments for conditions including hypertension, hypercholesterolemia, asymptomatic left ventricular systolic dysfunction, and diabetes that impact HF incidence.
  • To assess the effectiveness of various therapeutic interventions in reducing the occurrence of heart failure.

Main Methods:

  • Conducted PubMed/MEDLINE searches to identify relevant treatment trials and observational studies.
  • Analyzed data on HF incidence reported in trials for hypertension, hypercholesterolemia, left ventricular systolic dysfunction, and diabetes.

Main Results:

  • Hypertension treatment reduced HF incidence by approximately 50%, with diuretics, beta-blockers, and ACE inhibitors showing greater efficacy.
  • Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors reduced HF incidence by about 20% in patients with hypercholesterolemia and coronary artery disease.
  • ACE inhibitors demonstrated significant HF risk reduction in patients with reduced systolic function (37%) and coronary artery disease (23%).
  • Better glycemic control in diabetes correlated with lower HF incidence, though effective therapies are underused, particularly hypertension management.

Conclusions:

  • Clinical trial results indicate substantial potential to reduce HF suffering and economic burden through improved clinical practice.
  • Enhanced control of hypertension, primary prevention of myocardial infarction, and broader adoption of secondary prevention measures are critical for reducing HF prevalence.
Abstract

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...